PMID- 30459612
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240403
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 9
DP  - 2018
TI  - Maintenance Chemotherapy With Chinese Herb Medicine Formulas vs. With Placebo in 
      Patients With Advanced Non-small Cell Lung Cancer After First-Line Chemotherapy: 
      A Multicenter, Randomized, Double-Blind Trial.
PG  - 1233
LID - 10.3389/fphar.2018.01233 [doi]
LID - 1233
AB  - Background: Chinese Herb Medicine Formulas (CHMF) was reported to improve the 
      quality of life (QoL) in advanced NSCLC patients. The present study was designed 
      to investigate whether maintenance chemotherapy plus CHMF in patients would 
      improve QoL and progression-free survival (PFS). Methods: Seventy-one patients 
      were enrolled from 8 medical centers in China, and were randomly assigned to a 
      maintenance chemotherapy plus CHMF group (n = 35) or a maintenance chemotherapy 
      plus placebo group (n = 36). The outcome measures included PFS, Karnofsky 
      performance status (KPS) scores, QoL (assessed with the lung cancer symptom scale 
      (LCSS) questionnaire), and adverse events (AEs). Results: Patients in the CHMF 
      group showed significant improvements in median PFS (HR = 0.55, 95% CI 0.28-0.88, 
      P = 0.019), KPS scores (P = 0.047), fatigue (cycle [C] 3: P = 0.03), interference 
      with daily activities (C3: P = 0.04) and dyspnea (C2: P = 0.03) compared with 
      patients in the placebo group. Compared with the placebo group, the incidence of 
      AEs decreased in the CHMF group, including loss of appetite (C2: P = 0.011, C4: P 
      = 0.004) and dry mouth (C4: P = 0.011). Conclusion: The essential finding of our 
      study is that maintenance chemotherapy combined with CHMF may prolong PFS, 
      relieve symptoms, improve QoL and alleviate the side effects.
FAU - Wang, Qin
AU  - Wang Q
AD  - Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
FAU - Jiao, Lijing
AU  - Jiao L
AD  - Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
AD  - Institute of Clinical Immunology, Yueyang Hospital of Integrated Traditional 
      Chinese and Western Medicine, Shanghai University of Traditional Chinese 
      Medicine, Shanghai, China.
FAU - Wang, Shengfei
AU  - Wang S
AD  - Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, 
      Shanghai, China.
FAU - Chen, Peiqi
AU  - Chen P
AD  - Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
FAU - Bi, Ling
AU  - Bi L
AD  - Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
FAU - Zhou, Di
AU  - Zhou D
AD  - Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
FAU - Yao, Jialin
AU  - Yao J
AD  - Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
FAU - Li, Jiaqi
AU  - Li J
AD  - Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
FAU - Chen, Zhiwei
AU  - Chen Z
AD  - Lung Tumor Clinical Medical Center, Shanghai Chest Hospital, Shanghai Jiaotong 
      University, Shanghai, China.
FAU - Jia, Yingjie
AU  - Jia Y
AD  - Department of Oncology, First Hospital Affiliated to Tianjin College of 
      Traditional Chinese Medicine, Tianjin, China.
FAU - Zhang, Ziwen
AU  - Zhang Z
AD  - Department of Oncology, Changshu the 2nd People's Hospital, Jiangsu, China.
FAU - Shen, Weisheng
AU  - Shen W
AD  - Department of Oncology, Affiliated Jiang-yin Hospital of the Southeast University 
      Medical College, Jiangsu, China.
FAU - Zhu, Weirong
AU  - Zhu W
AD  - Department of Traditional Chinese Medicine, Ruijin Hospital Affiliated to 
      Shanghai Jiaotong University School of Medicine, Shanghai, China.
FAU - Xu, Jianfang
AU  - Xu J
AD  - Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of 
      Medicine, Shanghai, China.
FAU - Gao, Yong
AU  - Gao Y
AD  - Department of Oncology, Shanghai East Hospital, Tongji University School of 
      Medicine, Shanghai, China.
FAU - Gong, Yabin
AU  - Gong Y
AD  - Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
FAU - Xu, Ling
AU  - Xu L
AD  - Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and 
      Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 
      China.
AD  - Tumor Institute of Traditional Chinese Medicine, Longhua Hospital, Shanghai 
      University of Traditional Chinese Medicine, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20181106
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC6232388
OTO - NOTNLM
OT  - NSCLC
OT  - adverse events
OT  - chinese herb medicine formulas
OT  - maintenance chemotherapy
OT  - quality of life
EDAT- 2018/11/22 06:00
MHDA- 2018/11/22 06:01
PMCR- 2018/11/06
CRDT- 2018/11/22 06:00
PHST- 2018/07/07 00:00 [received]
PHST- 2018/10/11 00:00 [accepted]
PHST- 2018/11/22 06:00 [entrez]
PHST- 2018/11/22 06:00 [pubmed]
PHST- 2018/11/22 06:01 [medline]
PHST- 2018/11/06 00:00 [pmc-release]
AID - 10.3389/fphar.2018.01233 [doi]
PST - epublish
SO  - Front Pharmacol. 2018 Nov 6;9:1233. doi: 10.3389/fphar.2018.01233. eCollection 
      2018.